Molecular mechanisms of therapy resistance in solid tumors: chasing "moving" targets (Q39172297)

9 September 2017

title

Molecular mechanisms of therapy resistance in solid tumors: chasing "moving" targets (English)

1 reference

9 September 2017

Laura J Tafe

1

1 reference

9 September 2017

publication date

10 March 2017

1 reference

9 September 2017

1 reference

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

9 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2101-7

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2101-7

Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2101-7

Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2101-7

Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2101-7

Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2101-7

EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2101-7

Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2101-7

Acquired resistance to TKIs in solid tumours: learning from lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2101-7

Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2101-7

Heterogeneity of resistance mutations detectable by next-generation sequencing in TKI-treated lung adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2101-7

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2101-7

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2101-7

Acquired resistance mechanisms to tyrosine kinase inhibitors in lung cancer with activating epidermal growth factor receptor mutation--diversity, ductility, and destiny

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2101-7

Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2101-7

Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2101-7

Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2101-7

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2101-7

HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2101-7

Histological transformation of ALK rearranged adenocarcinoma into small cell lung cancer: A new mechanism of resistance to ALK inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2101-7

Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2101-7

Epidermal growth factor receptor mutations in small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2101-7

Epidermal growth factor receptor mutations in small cell lung cancer: a brief report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2101-7

Comprehensive genomic profiles of small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2101-7

Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2101-7

Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2101-7

RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2101-7

Histopathological transformation to small-cell lung carcinoma in non-small cell lung carcinoma tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2101-7

NOTCH, ASCL1, p53 and RB alterations define an alternative pathway driving neuroendocrine and small cell lung carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2101-7

Cell of origin of small cell lung cancer: inactivation of Trp53 and Rb1 in distinct cell types of adult mouse lung.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2101-7

Identification of cancer initiating cells in K-Ras driven lung adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2101-7

Multiple cells-of-origin of mutant K-Ras-induced mouse lung adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2101-7

Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2101-7

Epithelial-mesenchymal transitions in development and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2101-7

The ZEB/miR-200 feedback loop--a motor of cellular plasticity in development and cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2101-7

Epithelial mesenchymal transition in drug resistance and metastasis of lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2101-7

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2101-7

Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2101-7

ZEB1 drives epithelial-to-mesenchymal transition in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2101-7

Key roles of EMT for adaptive resistance to MEK inhibitor in KRAS mutant lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2101-7

Peroxisome proliferator-activated receptor-gamma activation inhibits tumor metastasis by antagonizing Smad3-mediated epithelial-mesenchymal transition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2101-7

Resveratrol inhibits TGF-β1-induced epithelial-to-mesenchymal transition and suppresses lung cancer invasion and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2101-7

Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2101-7

Effective combination therapies in preclinical endocrine resistant breast cancer models harboring ER mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2101-7

ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2101-7

Incidence and clinical significance of ESR1 mutations in heavily pretreated metastatic breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2101-7

ESR1 mutations: Moving towards guiding treatment decision-making in metastatic breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2101-7

MED15 overexpression in prostate cancer arises during androgen deprivation therapy via PI3K/mTOR signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2101-7

Development of a second-generation antiandrogen for treatment of advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2101-7

Integrative clinical genomics of advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2101-7

Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2101-7

Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2101-7

Targeting DNA Repair: The Role of PARP Inhibition in the Treatment of Castration-Resistant Prostate Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2101-7

AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2101-7

Analytical Validation and Clinical Qualification of a New Immunohistochemical Assay for Androgen Receptor Splice Variant-7 Protein Expression in Metastatic Castration-resistant Prostate Cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2101-7

The retinoblastoma tumor suppressor controls androgen signaling and human prostate cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2101-7

Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2101-7

Rb loss is characteristic of prostatic small cell neuroendocrine carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2101-7

Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2101-7

Shared TP53 gene mutation in morphologically and phenotypically distinct concurrent primary small cell neuroendocrine carcinoma and adenocarcinoma of the prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2101-7

Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2101-7

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2101-7

Circulating DNA in diagnosis and monitoring EGFR gene mutations in advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2101-7

Circulating tumour DNA and resistance mechanisms during EGFR inhibitor therapy in lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2101-7

Prospective Validation of Rapid Plasma Genotyping for the Detection of EGFR and KRAS Mutations in Advanced Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2101-7

Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2101-7

Detection of the T790M mutation of EGFR in plasma of advanced non-small cell lung cancer patients with acquired resistance to tyrosine kinase inhibitors (West Japan oncology group 8014LTR study)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2101-7

Circulating Tumor Cells and Circulating Tumor DNA: Challenges and Opportunities on the Path to Clinical Utility

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2101-7

Genomic Approaches to Understanding Response and Resistance to Immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2101-7

Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2101-7

Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2101-7

Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2101-7

Molecular and genetic properties of tumors associated with local immune cytolytic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2101-7

Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2101-7

Small cell lung cancer transformation and T790M mutation: complimentary roles in acquired resistance to kinase inhibitors in lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2101-7

AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2101-7

Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2101-7

The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2101-7

EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2101-7

Acquired Resistance of EGFR-Mutant Lung Cancer to a T790M-Specific EGFR Inhibitor: Emergence of a Third Mutation (C797S) in the EGFR Tyrosine Kinase Domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2101-7

Heterogeneous mechanisms of primary and acquired resistance to third-generation EGFR inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2101-7

Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2101-7

Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2101-7

Emergence of resistance to tyrosine kinase inhibitors in non-small-cell lung cancer can be delayed by an upfront combination with the HSP90 inhibitor onalespib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2101-7

Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2101-7

Understanding Mechanisms of Resistance in the Epithelial Growth Factor Receptor in Non-Small Cell Lung Cancer and the Role of Biopsy at Progression

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/28280929

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S00428-017-2101-7

1 reference

9 September 2017

1 reference